Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases..
We characterized 53 OXA-48-producing Klebsiella pneumoniae (OXA-48-Kp) isolated between 2011 and 2013 in 21 French hospitals. All the isolates were genotyped using MLST and PFGE and the population structure of the species was determined by a nucleotide-based analysis of the entire K. pneumoniae MLST database. Most of the OXA-48-Kp isolates also produced CTX-M-15 and remained susceptible to imipenem and meropenem. The isolates were distributed into 20 STs, of which five were dominant (ST15, ST101, ST147, ST395 and ST405). All the OXA-48-Kp clustered in the major clade of K. pneumoniae KpI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 20(2014), 12 vom: 17. Dez., Seite O1121-3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liapis, E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.08.2015 Date Revised 09.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1469-0691.12727 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM239304640 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM239304640 | ||
| 003 | DE-627 | ||
| 005 | 20231224115643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1469-0691.12727 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0797.xml |
| 035 | |a (DE-627)NLM239304640 | ||
| 035 | |a (NLM)24942039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liapis, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular epidemiology of OXA-48-producing Klebsiella pneumoniae in France |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.08.2015 | ||
| 500 | |a Date Revised 09.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. | ||
| 520 | |a We characterized 53 OXA-48-producing Klebsiella pneumoniae (OXA-48-Kp) isolated between 2011 and 2013 in 21 French hospitals. All the isolates were genotyped using MLST and PFGE and the population structure of the species was determined by a nucleotide-based analysis of the entire K. pneumoniae MLST database. Most of the OXA-48-Kp isolates also produced CTX-M-15 and remained susceptible to imipenem and meropenem. The isolates were distributed into 20 STs, of which five were dominant (ST15, ST101, ST147, ST395 and ST405). All the OXA-48-Kp clustered in the major clade of K. pneumoniae KpI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Multidrug resistance | |
| 650 | 4 | |a multilocus sequence typing | |
| 650 | 4 | |a phylogenetic analysis | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Thienamycins |2 NLM | |
| 650 | 7 | |a Imipenem |2 NLM | |
| 650 | 7 | |a 71OTZ9ZE0A |2 NLM | |
| 650 | 7 | |a beta-lactamase CTX-M-15 |2 NLM | |
| 650 | 7 | |a EC 3.5.2.- |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a oxacillinase |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a Meropenem |2 NLM | |
| 650 | 7 | |a FV9J3JU8B1 |2 NLM | |
| 700 | 1 | |a Pantel, A |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, J |e verfasserin |4 aut | |
| 700 | 1 | |a Nicolas-Chanoine, M-H |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalié, L |e verfasserin |4 aut | |
| 700 | 1 | |a van der Mee-Marquet, N |e verfasserin |4 aut | |
| 700 | 1 | |a de Champs, C |e verfasserin |4 aut | |
| 700 | 1 | |a Aissa, N |e verfasserin |4 aut | |
| 700 | 1 | |a Eloy, C |e verfasserin |4 aut | |
| 700 | 1 | |a Blanc, V |e verfasserin |4 aut | |
| 700 | 1 | |a Guyeux, C |e verfasserin |4 aut | |
| 700 | 1 | |a Hocquet, D |e verfasserin |4 aut | |
| 700 | 1 | |a Lavigne, J-P |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, X |e verfasserin |4 aut | |
| 700 | 0 | |a ONERBA |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 20(2014), 12 vom: 17. Dez., Seite O1121-3 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2014 |g number:12 |g day:17 |g month:12 |g pages:O1121-3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1469-0691.12727 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2014 |e 12 |b 17 |c 12 |h O1121-3 | ||